The Castleman disease treatment market exhibits distinct regional characteristics that reflect varying rare disease diagnostic capabilities, access to biologic therapies, healthcare infrastructure, and research expertise. North America retained market leadership with 41.2% of global share in 2025, underpinned by the United States' dominant position in rare disease drug development and access, with the FDA's orphan drug program providing market exclusivity incentives and the Castleman Disease Collaborative Network headquartered at the University of Pennsylvania driving research and clinical trial infrastructure. Over 1,200 Castleman disease patients were under active treatment in U.S. academic and community centers by 2025, with siltuximab available through specialty pharmacies and expanded access programs for eligible patients. The U.S. National Institutes of Health supports Castleman disease research through the National Cancer Institute and National Institute of Allergy and Infectious Diseases, while patient advocacy organizations including the Castleman Disease Collaborative Network and the CDCN Foundation drive awareness and funding.

Europe commands 28.6% of global market share, with the United Kingdom, Germany, France, and Italy serving as leading treatment centers. Castleman Disease Treatment Market analysis shows that the European Medicines Agency approved siltuximab for iMCD in 2014, with national reimbursement varying by country and healthcare system. Over 680 Castleman disease patients received active treatment across European centers in 2025, with strong concentration in hematology and internal medicine departments at university hospitals. The European Reference Network on Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) supports cross-border expertise sharing and patient referral. The UK's National Health Service provides siltuximab through specialized commissioning, while Germany's statutory health insurance covers off-label tocilizumab use when clinically indicated.

Asia-Pacific is pacing ahead as the fastest-growing region with a 10.4% CAGR projected through 2035, driven by improving diagnostic capabilities, expanding access to biologic therapies, and growing awareness among hematologists. China has established Castleman disease diagnosis and treatment capabilities in major tertiary hospitals, with tocilizumab and rituximab widely available and siltuximab accessible through import channels for eligible patients. Japan's Ministry of Health, Labour and Welfare approved siltuximab in 2017, with strong uptake in hematology departments. South Korea's advanced healthcare infrastructure supports diagnosis and treatment, while India's emerging rare disease programs and expanding biologics access create growth potential. Australia's Therapeutic Goods Administration approved siltuximab with PBS reimbursement for eligible patients. The competitive landscape is concentrated in approved therapies, with EUSA Pharma/Jazz Pharmaceuticals' siltuximab controlling approximately 58% of targeted therapy revenues and Roche's tocilizumab capturing significant off-label share. However, emerging biopharmaceutical companies including Xencor, which is developing IL-6-directed therapies, and numerous academic investigators are advancing novel approaches. Entry barriers include small patient populations, complex trial design for rare diseases, regulatory expertise, and established treatment relationships, yet opportunities persist in combination regimens, novel targets, and emerging market access expansion.

Q1: Which region leads the global Castleman disease treatment market? North America dominates with 41.2% market share in 2025, supported by FDA orphan drug incentives, the Castleman Disease Collaborative Network, NIH research funding, and over 1,200 actively treated patients.

Q2: What makes Asia-Pacific the fastest-growing region? Asia-Pacific grows at 10.4% CAGR due to improving diagnostics in China, Japan's 2017 siltuximab approval, expanding biologics access, and growing hematologist awareness across the region.

Q3: Who are the leading companies in Castleman disease treatment? EUSA Pharma/Jazz Pharmaceuticals' siltuximab controls approximately 58% of targeted therapy revenues, with Roche's tocilizumab holding significant off-label share, and Xencor advancing novel IL-6-directed approaches.